A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer
| Autor: | Tae Won Kim, Sung Tae Oh, Yoon-Koo Kang, Byung Sik Kim, Sung Sook Lee, Sun Jin Sym, Jae-Lyun Lee, Jeong Hwan Yook, Min-Hee Ryu, Hye Jin Kang, Heung Moon Chang |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Gastrointestinal Diseases medicine.medical_treatment Phases of clinical research Docetaxel Adenocarcinoma Irinotecan Toxicology Stomach Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) neoplasms Survival analysis Aged Pharmacology Chemotherapy business.industry Remission Induction Combination chemotherapy Middle Aged Advanced gastric cancer Hematologic Diseases Survival Analysis digestive system diseases Clinical trial stomatognathic diseases Asthenia Disease Progression Camptothecin Female Taxoids business therapeutics medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology. 63:1-8 |
| ISSN: | 1432-0843 0344-5704 |
| Popis: | Irinotecan (I) and docetaxel (D), each of which has a unique mechanism of action, were recently introduced in the treatment of patients with advanced gastric cancer (AGC). We have evaluated the efficacy and safety of the ID combination for AGC patients after failure of fluoropyrimidine- or platinum-based chemotherapy.Patients with relapsed or progressive AGC after prior fluoropyrimidine- or platinum-based chemotherapy were treated with I (160 mg/m(2), 90 min) followed by D (65 mg/m(2), 1 h) every 3 weeks. Because of the unacceptable toxicity among the first ten patients, the doses were reduced for I (120 mg/m(2)) and D (50 mg/m(2)) every 3 weeks.Forty-nine patients, of median age 53 years (range, 27-68 years), were treated with 170 cycles of chemotherapy (median, 2 cycles; range, 1-12 cycles). Three patients achieved complete response and seven achieved partial response, resulting in an overall response rate (ORR) of 20.4% [95% confidence interval (CI), 9.1-31.7%], with a median duration of 7.1 months (range: 2.1-69.1 months). ORR was 60% (95% CI, 29.6-90.3%) for the higher dose and 10.3% (95% CI, 0.7-19.8%) for the lower dose. Median time to progression for all patients was 2.7 months (95% CI, 1.7-3.8 months) and the median overall survival was 8.9 months (95% CI, 6.6-11.3 months). Grade 3/4 toxicities included neutropenia (90%), febrile neutropenia (50%), asthenia (40%), and diarrhea (10%) with the higher dose and neutropenia (71%), febrile neutropenia (11%), diarrhea (24%), and asthenia (24%) with the lower dose. There were two possible treatment-related deaths.The combination of irinotecan and docetaxel, once every three weeks shows anti-tumor activity but is not feasible as a second-line treatment for AGC patients after failure of fluoropyrimidine- or platinum-based chemotherapy due to the high rate of toxicities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink